Physician

Ben Yiming Zhang, MD

According to 2025 Medicare claims, Ben Zhang, MD (NPI: 1366738098) practices hematology/oncology in the Minneapolis-St. Paul-Bloomington, MN-WI market, with the plurality of this provider's patient population coming from Dakota, MN. This provider's primary affiliated billing organization is MINNESOTA ONCOLOGY HEMATOLOGY, PA (NPI: 1528035995; TIN: 411793418) and primary practice location at 55337-6743. Zhang is affiliated with the Mayo Clinic Community ACO, LLC (ACO ID: A4617), participating under the MSSP model.

Zhang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 389 traditional Medicare patients, billed 148,405 HCPCS/CPT codes, and received $3,345,757 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,973 prescription claims across 250 beneficiaries totaling $7,282,537 in drug costs, led by Revlimid (Lenalidomide). DME data shows 46 claims. Open Payments data shows 12 records totaling $363,097. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $8,092 to $3,345,757. Similarly, Part D prescription costs have risen steadily, from $76,864 to $7,282,537. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,718 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	65	103	$8,092
2016	48	88	$6,884
2017	90	1,098	$28,548
2018	133	11,510	$129,663
2019	482	146,300	$2,211,196
2020	410	149,341	$2,751,438
2021	376	153,247	$2,953,909
2022	393	157,596	$2,650,887
2023	399	139,151	$2,490,459
2024	389	148,405	$3,345,757

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	41	138	$76,864
2016	15	55	$38,074
2017	44	172	$208,185
2018	99	493	$616,409
2019	203	1,112	$2,950,875
2020	206	1,419	$3,808,135
2021	199	1,626	$4,724,483
2022	211	1,448	$4,472,819
2023	219	1,574	$4,266,735
2024	250	1,973	$7,282,537

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	17	$18
2016	N/R	N/R	N/R
2017	N/R	12	$33
2018	N/R	N/R	N/R
2019	N/R	38	$1,404
2020	N/R	44	$1,907
2021	N/R	25	$1,088
2022	N/R	59	$2,735
2023	N/R	N/R	N/R
2024	N/R	46	$903

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	82	333	$106
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	209	626	$97
80053	Blood test, comprehensive group of blood chemicals	194	640	$10
36415	Insertion of needle into vein for collection of blood sample	222	930	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	230	997	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	113	2,662	$1,419,536
Lenvima	Lenvatinib Mesylate	37	1,110	$847,909
Pomalyst	Pomalidomide	35	903	$660,224
Lenalidomide	Lenalidomide	57	1,386	$573,247
Imbruvica	Ibrutinib	37	1,060	$500,748

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	22	$414
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$326
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$217	Davol Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	9	$362,880	BeiGene, Ltd.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ben Yiming Zhang, MD?

Tedicare shows public-source Medicare data for Ben Yiming Zhang, MD (NPI 1366738098), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ben Yiming Zhang, MD have ACO affiliation data?

Ben Yiming Zhang, MD is shown with ACO affiliation data for Mayo Clinic Community ACO, LLC (MSSP, ACO ID A4617).

What billing organization is linked to Ben Yiming Zhang, MD?

Ben Yiming Zhang, MD is linked to MINNESOTA ONCOLOGY HEMATOLOGY, PA (billing NPI 1528035995) in the available physician profile data.

Does Ben Yiming Zhang, MD have Open Payments data?

Ben Yiming Zhang, MD has 12 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.